unknown
Stage
About
Genetix Biotherapeutics (formerly bluebird bio) develops one-time administered gene therapies that target the underlying causes of rare genetic diseases, including sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. The company focuses on advancing first-in-class genetic therapies from development toward patient access.
Explore Genetix Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.